STOCK TITAN

Beam Therapeutics to Participate in the 2022 Jefferies Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Beam Therapeutics (Nasdaq: BEAM) will have CEO John Evans engage in a fireside chat during the 2022 Jefferies Healthcare Conference on June 10, 2022, at 9:30 a.m. ET in New York City. The event will be accessible via a live webcast on the company's website, with a recording available for 60 days post-event. Beam is dedicated to pioneering precision genetic medicines using its base editing technology, aimed at providing lifelong cures for serious diseases through precise genomic editing.

Positive
  • None.
Negative
  • None.

CAMBRIDGE, Mass., June 03, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer, will participate in a fireside chat during the 2022 Jefferies Healthcare Conference on Friday, June 10, 2022 at 9:30 a.m. ET in NYC.

A live webcast will be available in the investor section of the company's website at www.beamtx.com, and will be archived for 60 days following the presentation.

About Beam Therapeutics
Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform that includes a suite of gene editing and delivery technologies and is in the process of building internal manufacturing capabilities. Beam’s suite of gene editing technologies is anchored by base editing, a proprietary technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This has the potential to enable a wide range of potential therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing life-long cures to patients suffering from serious diseases.

Contacts:

Investors:
Chelcie Lister
THRUST Strategic Communications
chelcie@thrustsc.com

Media:
Dan Budwick
1AB
dan@1abmedia.com


FAQ

When is Beam Therapeutics' CEO participating in the Jefferies Healthcare Conference?

John Evans, CEO of Beam Therapeutics, will participate in the Jefferies Healthcare Conference on June 10, 2022.

What time will Beam Therapeutics' presentation take place at the conference?

The fireside chat will take place at 9:30 a.m. ET.

How can I watch the Beam Therapeutics presentation?

The presentation will be available as a live webcast on Beam's website and archived for 60 days.

What is Beam Therapeutics known for?

Beam Therapeutics focuses on precision genetic medicines using innovative base editing technology.

What potential benefits does Beam's technology offer?

Beam's base editing technology can enable precise genomic edits without causing double-stranded breaks, potentially leading to lifelong cures.

Beam Therapeutics Inc.

NASDAQ:BEAM

BEAM Rankings

BEAM Latest News

BEAM Stock Data

2.27B
81.62M
1.42%
93.14%
14.45%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
CAMBRIDGE